Chugai Pharmaceutical and Araris Biotech AG enter into license agreement for Araris’ linker-payload ADC technology, AraLinQ

CAR-T Digest - August 2020

10 February 2026: Chugai Pharmaceutical and Araris Biotech AG enter into license agreement for Araris’ linker-payload ADC technology, AraLinQ

Chugai Pharmaceutical and Araris Biotech announced that Chugai has exercised its option under a previously established collaboration agreement to license Araris’ proprietary AraLinQ linker-payload platform for the development of novel antibody drug conjugates against a target selected by Chugai
The agreement enables Chugai to integrate AraLinQ technology designed to conjugate multiple anticancer payloads to a single antibody with its own antibody engineering capabilities, aiming to generate next-generation ADCs with improved tumor selectivity, efficacy, and safety
For Araris, the option exercise represents a key milestone that validates the scientific progress achieved through the collaboration and reinforces its positioning as a partner for differentiated multi-payload ADC platforms with enhanced linker stability and antibody-like pharmacokinetics
Under the terms of the agreement, Araris will receive an upfront payment and may be eligible for additional development and commercial milestone payments, as well as royalties on potential future sales
If all options and milestones under the broader agreement are achieved, the total potential consideration to Araris could reach approximately US$780 million, underscoring the strategic value of advanced linker-payload technologies in the evolving ADC landscape